Retatrutide Research Compound
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
Retatrutide (LY3437943) is a groundbreaking triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors. This next-generation peptide represents the most advanced incretin-based research compound, with Phase 2 clinical data demonstrating unprecedented efficacy in metabolic studies with >24% reduction observed in clinical trials.
Molecular Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C191H296N50O61 |
| Molecular Weight | 4156.68 g/mol |
| CAS Number | 2381089-83-2 |
| Amino Acids | 39 |
| Purity | ≥98% (HPLC) |
| Storage | -20°C, protected from light |
Mechanism of Action
Retatrutide provides balanced activation of three metabolic hormone receptors:
GLP-1 Receptor Agonism
- Glucose-dependent insulin secretion
- Appetite suppression via CNS pathways
- Delayed gastric emptying
GIP Receptor Agonism
- Enhanced insulin secretion
- Beta-cell trophic effects
- Potential adipose tissue modulation
Glucagon Receptor Agonism
- Increased energy expenditure
- Enhanced lipid oxidation
- Hepatic glucose regulation
The triple mechanism creates synergistic effects that exceed dual or single agonists in metabolic research applications.
Research Applications
Triple Receptor Signaling Studies
- Receptor cross-talk mechanisms
- Comparative efficacy analysis
- Dose-response optimization
Energy Metabolism Research
- Thermogenesis and energy expenditure
- Lipid oxidation pathways
- Substrate utilization studies
Advanced Metabolic Studies
- Multi-receptor signal integration
- Long-term metabolic adaptation
- Tissue-specific effects
Available Formats
| Size | Format | Catalog Code |
|---|---|---|
| 5mg | Lyophilized | RET-5 |
| 10mg | Lyophilized | RET-10 |
| 15mg | Lyophilized | RET-15 |
Handling & Storage
- Store lyophilized peptide at -20°C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8°C for up to 3 weeks
- Avoid freeze-thaw cycles
Quality Specifications
- Purity: ≥98% by HPLC
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in sterile water
- Endotoxin: Less than 1 EU/mg
- Certificate of Analysis provided
References
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." N Engl J Med. 2023.
- Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes." Lancet. 2023.
- Coskun T, et al. "LY3437943, a Novel Triple Agonist for GIP, GLP-1, and Glucagon Receptors." Cell Metab. 2022.